Jun Zhu

7.4k total citations
177 papers, 2.5k citations indexed

About

Jun Zhu is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Jun Zhu has authored 177 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 113 papers in Pathology and Forensic Medicine, 88 papers in Oncology and 49 papers in Genetics. Recurrent topics in Jun Zhu's work include Lymphoma Diagnosis and Treatment (111 papers), Chronic Lymphocytic Leukemia Research (46 papers) and Viral-associated cancers and disorders (40 papers). Jun Zhu is often cited by papers focused on Lymphoma Diagnosis and Treatment (111 papers), Chronic Lymphocytic Leukemia Research (46 papers) and Viral-associated cancers and disorders (40 papers). Jun Zhu collaborates with scholars based in China, Ethiopia and United States. Jun Zhu's co-authors include Yuqin Song, Weiping Liu, Xiaopei Wang, Lingyan Ping, Zhitao Ying, Yan Xie, Wen Zheng, Ningjing Lin, Lijuan Deng and Meifeng Tu and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jun Zhu

157 papers receiving 2.5k citations

Peers

Countries citing papers authored by Jun Zhu

Since Specialization

Citations

This map shows the geographic impact of Jun Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Zhu more than expected).

Fields of papers citing papers by Jun Zhu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jun Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Zhu. The network helps show where Jun Zhu may publish in the future.

Co-authorship network of co-authors of Jun Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Jun Zhu. A scholar is included among the top collaborators of Jun Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jun Zhu. Jun Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Reprocessable non-isocyanate polyurethane foams from lignin: A sustainable route to high-performance thermal insulation materials 2025 ·Chemical Engineering Journal ·Jun Zhu, (unknown), (unknown), (unknown), Jian Chen, Can Jin, Guomin Wu, Guifeng Liu	0
2	Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial 2024 ·BMC Medicine ·Yanfei Liu, Lingyan Ping, Yuqin Song, (unknown), Wen Zheng, Weiping Liu, Zhitao Ying, Chen Zhang, (unknown), Feier Feng, Ningjing Lin, Meifeng Tu, Jun Zhu, Yan Xie	2
3	Phase I safety and preliminary efficacy of IMM0306 in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma. 2024 ·Journal of Clinical Oncology ·Yanyan Liu, Ningjing Lin, Zhihua Yao, (unknown), (unknown), (unknown), (unknown), Wenzhi Tian, Yuqin Song, Jun Zhu	1
4	Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma 2024 ·Leukemia & lymphoma ·Yuqin Song, Jianyong Li, Keshu Zhou, (unknown), (unknown), Huilai Zhang, (unknown), Zhen Xia, Yiqiu Wang, (unknown), Xiaofeng Liu, Jun Zhu	1
5	Three-dimensional conformal radiation therapy with concurrent chemotherapy for stage III non-small cell lung cancer: protocol for a systematic review and meta-analysis 2024 ·BMJ Open ·(unknown), (unknown), (unknown), Jun Zhu, (unknown), (unknown), Weijuan Li, (unknown)	1
6	822P Preliminary results from a phase Ib study of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma 2024 ·Annals of Oncology ·Liping Deng, Yong-Wen Song, (unknown), Ning Lin, Zilong Yao, Jianqi Zhang, Wei Meng, Zhimin Wang, Qiang Lü, Weidong Tian, Jun Zhu	1
7	The mTOR kinase inhibitor everolimus synergistically enhances the anti‐tumor effect of the Janus kinase 1 (JAK1) inhibitor AZD4205 on Peripheral T cell lymphoma 2023 ·Hematological Oncology ·(unknown), Mingming Wu, Lan Mi, Hongjie Yu, Da Wang, Dahai Hu, Jing Cao, Ning Ding, Xiaoyang Wang, Yuqin Song, Shi Shu, (unknown), Jun Zhu	1
8	Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study 2023 ·Cytotherapy ·Zhitao Ying, Haiyan Yang, Ye Guo, Wenyu Li, Dehui Zou, Daobin Zhou, Zhao Wang, Mingzhi Zhang, Jianqiu Wu, Hui Liu, Chris Wang, (unknown), Su Yang, Zisong Zhou, Yun Qin, Yuqin Song, Jun Zhu	13
9	The Metabolism and Immune Environment in Diffuse Large B-Cell Lymphoma 2023 ·Metabolites ·Jianbo Wu, (unknown), (unknown), (unknown), (unknown), Yunkun Dang, Fan Lai, Longyan Yang, Mi Deng, Yuqin Song, Jun Zhu	5
10	PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2 2023 ·Hematological Oncology ·Laurie H. Sehn, Martine E.D. Chamuleau, Georg Lenz, Michael Roost Clausen, Corinne Haïoun, Koji Izutsu, Andrew Davies, Jun Zhu, Toshihiko Oki, Edith Szafer‐Glusman, (unknown), Hung‐Yi Chiou, David Ipe, (unknown), Jian Wu, Gilles Salles	4
11	Autologous hematopoietic stem cell transplantation improves survival outcomes in peripheral T-cell lymphomas: a multicenter retrospective real-world study 2023 ·Annals of Hematology ·(unknown), Feng‐Rong Wang, Shihua Zhao, Yajun Li, Wenrong Huang, Bo Nie, Haisheng Liu, Xiaoqian Liu, Wei Li, Haifeng Yu, (unknown), (unknown), Yujun Dong, Chenglu Yuan, (unknown), Xiubin Xiao, Weiping Liu, Jun Zhu	0
12	Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase 2020 ·Clinical Cancer Research ·Yuqin Song, Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Haiyi Guo, Lei Zhou, Rebecca Elstrom, Jane Huang, William Novotny, Rachel Wei, Jun Zhu	111
13	MiR-101 promotes nasopharyngeal carcinoma cell apoptosis through inhibiting Ras/Raf/MEK/ERK signaling pathway 2020 ·SHILAP Revista de lepidopterología ·(unknown), Enduo Qiu, Jun Zhu, (unknown), (unknown)	10
14	A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma 2019 ·Clinical Cancer Research ·Yuqin Song, Jianqiu Wu, Xinchuan Chen, Tongyu Lin, Junning Cao, Yanyan Liu, Yaozhong Zhao, Jie Jin, Haiwen Huang, Jianda Hu, (unknown), Liling Zhang, Hong‐Wei Xue, Qingyuan Zhang, Weiwei Wang, (unknown), Jifeng Feng, Jun Zhu	109
15	Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: a retrospective study 2019 ·Hematology ·(unknown), Lingyan Ping, Weiping Liu, Yan Xie, (unknown), Yanfei Liu, (unknown), Jun Zhu, (unknown), Yuqin Song	8
16	BGB-3111, a Highly Specific BTK Inhibitor, Is Well Tolerated and Highly Active in Chinese Patients with Relapsed/Refractory B-Cell Malignancies: Initial Report of a Phase 1 Trial in China 2017 ·Blood ·Jun Zhu, Jianyong Li, Jianfeng Zhou, Yuqin Song, Junyuan Qi, Wei Xu, Dengju Li, Mingyuan Sun, Ling Xue, Liudi Yang, (unknown), Lai Wang, Jane Huang, Shibao Feng, Lugui Qiu	3
17	Effect of Anti-Cyclic Citrullinated Peptide 2 Immunoglobulin M Serostatus on Efficacy Outcomes Following Treatment with Abatacept Plus Methotrexate 2015 ·Data Archiving and Networked Services (DANS) ·T. Huizinga, Seán Connolly, Alyssa Johnsen, Jun Zhu, D E Furst, (unknown), Gerd R Burmester, Bernard Combe, (unknown), Leendert A. Trouw, René E. M. Toes, P. Emery	1
18	FCGR3A 158V/F Polymorphism and Response to Frontline R-CHOP Therapy in Diffuse Large B-Cell Lymphoma 2014 ·DNA and Cell Biology ·Fen Liu, Huirong Ding, Xuan Jin, Ning Ding, Lijuan Deng, Yan He, Jun Zhu, Yuqin Song	13
19	[Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail]. 2005 ·PubMed ·Tong Lin, Hong Yu Zhang, Yan Huang, Zhong Zhen Guan, Tong Shen, Yuan Shi, Jun Zhu, (unknown), (unknown), (unknown), (unknown), Ting Liu, (unknown)	13
20	Induction of mixed hematopoietic chimerism and specific transplantation tolerance to allogeneic and xenogeneic grafts by selective elimination of donor-reactive host cells following nonmyeloablative conditioning 1997 ·Transplantation Proceedings ·Tatyana B. Prigozhina, Olga Gurevitch, Jun Zhu, S Slavin	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact